Navigation Links
Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Date:3/14/2014

March 14, 2014 Lebanon, NH - Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant. The researchers, led by Alexey V. Danilov, MD, PhD, assistant professor at the Geisel School of Medicine at Dartmouth and Hematologist-Oncologist at the Norris Cotton Cancer Center, modeled the lymph node microenvironment where CLL cells are found in the laboratory. They were able to disrupt the activity of a pathway (NF-kappaB) that ensures the survival and resistance of the CLL cells in such microenvironments. The study findings were published in the March 15, 2014 issue of Clinical Cancer Research.

"In this in vitro microenvironment, we used MLN4924 to disrupt the activity of the NF-kappaB pathway by targeting Nedd8, which controls activation of NF-kappaB," said Danilov. "This decreased the survival of CLL cells and re-sensitized them to conventional chemotherapy as well as novel agents. Because the CLL cells used were obtained from patients with this disorder, these findings are immediately relevant to the clinic."

Danilov says that unlike other novel therapies that have shown promise in the treatment of CLL, this approach is unique because it does not directly target proteins within the B-cell receptor pathway. He also notes that other research models that mimic the natural lymph node microenvironment have typically induced prolonged survival of CLL cells and made them resistant to in vitro chemotherapy. This research used novel model systems which reversed the pro-survival effects of the microenvironment.

The researchers are now working to understand the intricate mechanisms of how MLN4924 decreased the survival of CLL cells. Once they understand the mechanisms involved, new therapeutic approaches and drug combinations can be developed for use in animal studies of CLL, and may ultimately lead to a clinical trial with human patients.


'/>"/>

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Related medicine news :

1. Dartmouth researchers investigate the cognitive effects of athlete head impacts
2. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
3. Dartmouth medical research closes in on new tuberculosis vaccine
4. Leap in leukemia treatment reported by Dartmouth researchers
5. Dartmouth researchers test safety of Nivolumab in kidney cancer
6. Dartmouth researchers develop molecular switch that changes liquid crystal colors
7. Dartmouth researchers receive $5.9 million grant from NIH for lung research
8. Clemson, Dartmouth use $1.5M grant to develop mobile health technology
9. Dartmouth researcher finds novel genetic patterns that make us rethink biology and individuality
10. Dartmouth study provides first global evidence that foreign aid boosts public opinion
11. NIH awards $20 million over 5 years to train next generation of global health researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Thinksport, the leaders in safe, non-toxic ... sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, by ... aisles that contain harmful chemicals that should be put nowhere near your skin ...
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three ... The first new location will open at the corner of 27th and Randolph in ... Drive this fall. And the third location is in the process of being identified. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., ... announced it has completed a round of funding to accelerate its growth strategies. ... Black Granite Capital is a growth equity firm focused on investments in healthcare ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet ... adoption of e-prescribing as measured in Part D Medicare data. The dataset, called ... pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data ...
(Date:4/26/2017)... ... 26, 2017 , ... Infertility may be a result of ... helped many women become pregnant upon treating their diagnosis. , To ... evaluations. We can provide the necessary information to diagnose and treat your ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Cardiology devices segment is anticipated to ... The Cardiology Devices segment is likely to create absolute ... in 2018 over 2017. By the end of 2027, Cardiology ... to US$ 700 Mn, expanding at a CAGR of 18.4% ... Asia Pacific reprocessed medical devices market ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: